IFF and Kemira Form Joint Venture To Produce Sustainable Biobased Materials at Scale
IFF (NYSE:IFF) and Kemira announced the formation of Alpha Bio, a joint venture aimed at commercial-scale production of renewable biobased materials. With an investment of approximately €130 million, the Alpha Bio facility will start production in late 2027, converting up to 44,000 MT of plant sugars to bioproducts, including high-performance biopolymers for use in various applications, such as home and personal care and industrial solutions. Alpha Bio’s production will use IFF’s Designed Enzymatic Biomaterial™ (DEB) platform technology, integrated at the IFF biorefinery in Kotka, Finland.
"Our partnership with Kemira has reached a significant milestone, enabling us to scale the production of groundbreaking biobased materials to meet the large and growing demand for high-performing and sustainable alternatives to fossil-derived polymers," said Erik Fyrwald, IFF CEO. "IFF’s DEB technology not only guarantees superior purity and consistency compared to traditional biopolymers but also enhances performance across various applications. This innovative approach allows us to combine biodegradability and material sustainability while maintaining cost efficiency and the high performance our customers expect."
IFF’s DEB platform leverages biotechnology by using plant-based sugars and enzymes under mild process conditions to create biobased materials, which can be tailored for specific product applications. This allows manufacturers to replace traditional fossil-based synthetic polymers with more sustainable alternatives. This highly efficient enzymatic polymerization process converts plant sugars to biopolymers, offering superior purity and consistency compared to conventional synthetic polymers. These tailored biopolymers enhance product performance across diverse applications.
“Since 2020, we’ve been collaborating with IFF using the DEB platform technology, which has allowed us to bring sustainable innovation to our key markets,” said Antti Salminen, CEO, Kemira Oyj. “The new joint venture will build on this initial success, enabling us to scale up production and provide new performance-competitive alternatives to fossil-based products in key markets, including paper and board packaging, paper coatings, and water treatment, while continuing to develop opportunities across other growth markets.”
Operating as an independent entity in Kotka, Finland, the joint venture will manufacture a specific line of products enabled by DEB technology for exclusive use by IFF and Kemira. The creation of Alpha Bio is expected to generate approximately 30 direct new jobs in the Kotka area with additional job creation during the project’s construction phase.
Visit www.iff.com for more information.
Cautionary Statement under the Private Securities Litigation Reform Act of 1995
This press release contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “”plan”, “expect,” “anticipate,” “intend,” “believe,” “seek,” “see,” “will,” “would,” “target,” similar expressions, and variations or negatives of these words. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the timing or nature of the proposed expansion. The forward-looking statements included in this release are made only as of the date hereof, and we undertake no obligation to update the forward-looking statement to reflect subsequent events or circumstances.
Welcome to IFF
At IFF (NYSE: IFF), we make joy through science, creativity, and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook.
Welcome to Kemira
Kemira is a global leader in sustainable chemical solutions for water-intensive industries. We deliver tailored products and services to improve the product quality, processes, and resource efficiency of our diverse range of customers. Our focus is on water treatment, as well as on fiber and renewable solutions – enabling sustainability transformation for our customers. In 2024, Kemira reported annual revenue of EUR 2.9 billion with a global team of some 4,700 colleagues. Kemira is listed on the Nasdaq, Helsinki. More information: www.kemira.com
©2025 International Flavors & Fragrances Inc. (IFF). IFF, the IFF Logo, and all trademarks and service marks denoted with ™, ℠ or ® are owned by IFF or affiliates of IFF unless otherwise noted. All Rights Reserved.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250326146003/en/
Contacts
Media Relations:
Paulina Heinkel
332.877.5339
Media.request@iff.com
Investor Relations:
Michael Bender
212.708.7263
Investor.Relations@iff.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Geoquip Marine Secures €100million Bond to Accelerate Fleet Enhancements and Strategic Growth4.4.2025 09:00:00 CEST | Press Release
Geoquip Marine (Geoquip), a global leader in offshore geotechnical solutions and a Njord Partners portfolio company, is pleased to announce today it has successfully closed a €100million bond offering. This bond issuance significantly improves the Company’s cash balance, supports its continued growth, and is seen as a significant step in the Company’s ongoing maturation and development. The bond was placed after a successful roadshow with investors and will be used to advance key strategic initiatives. The immediate use of proceeds will be allocated between the repayment of existing debt and funding for two transformational projects: The Geoquip Silvretta: As announced in December, Geoquip Silvretta is currently in a shipyard in Norway undergoing work to create a state-of-the-art geotechnical services platform for the offshore energy sector. The vessel is on track to start operations in the first half of 2025. The Geoquip Elena: The Company is preparing to install a rig on Geoquip Elen
SES Announces Annual General Meeting Voting Results4.4.2025 08:50:00 CEST | Press Release
SES S.A. (“SES” or the “Company”) held the Company’s Annual General Meeting (“AGM”) at its headquarters in Betzdorf, Luxembourg, yesterday. The shareholders have voted all resolutions in accordance with the recommendations made by SES’s Board of Directors, notably the company’s 2024 annual accounts and the proposed annual dividend of EUR 0.50 per A-share (EUR 0.20 per B-share). The total amount includes the interim dividend of EUR 0.25 per A-share (EUR 0.10 per B-share) already paid to shareholders on 17 October 2024. The final dividend of EUR 0.25 per A-share (EUR 0.10 per B-share) will be paid to shareholders on 17 April 2025. Also as recommended by the Board of Directors, the shareholders approved the appointments of Mrs Ellen Lord and Mr John Shaw to the Board of Directors and the non-binding agenda item received from Atlas Infrastructure Partners regarding capital returns. “The outcome of the AGM is the result of SES’s ongoing commitment to productive shareholder engagement, ensur
ENHERTU ® Approved in the EU as First HER2 Directed Therapy for Patients with HR Positive, HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy4.4.2025 08:00:00 CEST | Press Release
Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) ENHERTU® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 low (IHC 1+ or IHC 2+/ISH-) or HER2 ultralow (IHC 0 with membrane staining) breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca. The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the DESTINY-Breast06 phase 3 trial presented at the 2024 American Society of Clinical Oncology (#
Western Union Offers Zero-Fee International Money Transfers to Myanmar4.4.2025 03:00:00 CEST | Press Release
In response to the devastating earthquake that recently struck Myanmar, Western Union today announced that it is offering consumers around the world zero-fee international money transfers1 to the country. Effective immediately until midnight, 00:00 Myanmar Standard Time on 10 April 2025, individuals can send funds to Myanmar via WesternUnion.com or the Western Union mobile app, ensuring families can provide crucial support to their loved ones during this time of urgent need. Western Union remains committed to providing support during times of crisis, offering zero-fee transfers whenever possible to help communities in need. Money transfers sent to Myanmar will be: Available for payout into bank accounts. Available for payout into select mobile wallets Available for payouts incash at Agent locations2 “Our thoughts are with the people of Myanmar during this incredibly difficult time,” said Atish Shrestha, Western Union’s Regional Director for Indochina, South Korea and Taiwan, Western Un
Clean Tech Leader Aymium Defeats Stora Enso at European Patent Office Boards of Appeal4.4.2025 00:07:00 CEST | Press Release
Cleantech leader Aymium defeated a challenge by Stora Enso to one of Aymium's patents (European Patent EP2697185) that provides exclusive rights to produce, sell and use bio-based materials for renewable battery applications. In its written opinion, the Boards of Appeal of the European Patent Office found Stora Enso's arguments brought before the board “not convincing” and agreed that a clarifying amendment to the claims did not extend the scope of protection of the patent. The ruling further affirms Aymium's position as the global leader in biocarbon materials for battery applications. Beyond the present ruling, Aymium owns a portfolio of more than 600 patents relating to biocarbon materials, compositions and manufacturing methods, including many specifically relevant to battery materials, and is the dominant global innovator regarding biocarbon materials. The ruling, combined with Aymium's massive patent portfolio, calls into question the ability of Stora Enso to produce bio-based ba
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom